Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
GTP binding elongation factor GUF1 (GUF1) is a highly conserved mitochondrial GTPase that acts as a fidelity factor during mitochondrial protein synthesis[1][5][6]. GUF1 binds to mitochondrial ribosomes in a GTP-dependent manner and catalyzes the backward translocation of tRNAs on the ribosome, helping to prevent amino acid misincorporation, especially under stressful or suboptimal conditions[1][4][5]. It possesses unique C-terminal domains crucial for tRNA interaction, which distinguishes it from other GTPases[1]. The gene is most highly expressed in the brain, with lower expression in the pancreas, and alternative splicing yields several transcript variants[1]. Mutations in GUF1 are associated with developmental and epileptic encephalopathy 40 (EIEE40), a severe neurodevelopmental disorder, implicating its essential role in mitochondrial function and neuronal health[5]. While not currently an established therapeutic target, GUF1 dysfunction is linked to neurological and possibly metabolic diseases[2][1][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on GTP binding elongation factor GUF1 (GUF1).